A Randomized, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Subcutaneous Administration of Lipegfilgrastim (Doses up to 100 μg/kg) in Healthy Japanese and Caucasian Subjects

Trial Profile

A Randomized, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Subcutaneous Administration of Lipegfilgrastim (Doses up to 100 μg/kg) in Healthy Japanese and Caucasian Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Lipegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Merckle
  • Most Recent Events

    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 23 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top